Solenn Brosseau

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa et al. · Science · 2017 · 5.4K citations

Life Sciences, Immunology, Oncology +17

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

Laura Mezquita, Édouard Auclin, Roberto Ferrara et al. · JAMA Oncology · 2018 · 951 citations · Full text

Life Sciences, Immunology, Oncology +17

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Roberto Ferrara, Laura Mezquita, Matthieu Texier et al. · JAMA Oncology · 2018 · 738 citations · Full text

Medicine, Oncology, Pharmacology +14

Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer

Sandra Assoun, Nathalie Théou–Anton, Marina Nguenang et al. · Lung Cancer · 2019 · 173 citations

Life Sciences, Immunology, Oncology +17

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Guillaume Manson, Alexandre Maria, F. Poizeau et al. · Journal for ImmunoTherapy of Cancer · 2019 · 106 citations · Full text

Life Sciences, Immunology, Oncology +17